Cargando…

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth factor and delta-like ligand 4, against platinum-resistant ovarian cancer. PATIENTS AND METHODS: This open-label, nonrandomized, dose-escalation...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Siqing, Corr, Bradley R., Culm-Merdek, Kerry, Mockbee, Colleen, Youssoufian, Hagop, Stagg, Robert, Naumann, R. Wendel, Wenham, Robert M., Rosengarten, Rafael D., Benjamin, Laura, Hamilton, Erika Paige, Moore, Kathleen N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9362870/
https://www.ncbi.nlm.nih.gov/pubmed/35439029
http://dx.doi.org/10.1200/JCO.21.01801

Ejemplares similares